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A human genome-wide linkage scan for obesity iden-
tified a linkage peak on chromosome 5q13–15. Posi-
tional cloning revealed an association of a rare haplo-
type to high body-mass index (BMI) in males but
not females. The risk locus contains a single gene,
‘‘arrestin domain-containing 3’’ (ARRDC3), an un-
characterized a-arrestin. Inactivating Arrdc3 in mice
led to a striking resistance to obesity, with greater
impact on male mice. Mice with decreased ARRDC3
levels were protected from obesity due to increased
energy expenditure through increased activity levels
and increased thermogenesis of both brown and
white adipose tissues. ARRDC3 interacted directly
with b-adrenergic receptors, and loss of ARRDC3
increased the response to b-adrenergic stimulation
in isolated adipose tissue. These results demonstrate
that ARRDC3 is a gender-sensitive regulator of
obesity and energy expenditure and reveal a sur-
prising diversity for arrestin family protein functions.INTRODUCTION
There is a significant genetic component to obesity, with herita-
bility estimated at 0.5–0.8 in twin studies (Stunkard et al., 1986).
However, relatively few common genetic variants have been
linked to obesity by genome-wide association studies, and
much of the genetic basis of obesity remains unexplained (Wal-
ley et al., 2009; O’Rahilly, 2009).
The b-arrestins, prototypical regulators of cell receptor
signaling and turnover, also have physiological roles in metabo-
lism. In particular, b-arrestin 2 regulates insulin receptor sig-
naling and may play a central role in diabetes (Luan et al.,
2009). The b- and visual arrestins are members of a larger and
more ancient family of arrestin-fold proteins that share structuralCell Msimilarity (Shi et al., 2006; Lin et al., 2008). A subfamily of
these arrestin-fold proteins has been termed the ‘‘a-arrestins’’
(Alvarez, 2008), although, as the structures of these proteins
are not known, definitive classification is lacking (Aubry et al.,
2009).
Mice and humans have at least five a-arrestins: ARRDC1–4
and thioredoxin-interacting protein (TXNIP). TXNIP, first identi-
fied as an inhibitor of thioredoxin, is known to regulate metabo-
lism and insulin responsiveness by inhibiting glucose uptake into
muscle and by shifting glucose usage from glycolytic to aerobic
pathways (Parikh et al., 2007; Chen et al., 2008; Chutkow et al.,
2010). However, TXNIP inhibits glucose uptake independent
of its interaction with thioredoxin, and this is a conserved func-
tion of at least one other a-arrestin (Patwari et al., 2009). The
a-arrestins may therefore have conserved roles in metabolism,
but their functions remain unclear.
We report here a male-specific association of ARRDC3 with
high body mass index (BMI) in humans and show that Arrdc3
deficiency in mice protects against obesity. These results reveal
the a-arrestins as a family of proteins with roles in regulation of
metabolism and the development of obesity.
RESULTS
Genome-Wide LInkage and Locus-Wide Association
to Male Overweight/Obesity at 5q13–15
A genome-wide linkage scan (GWLS) at an average intermarker
distance (marker density) of 4 cM, was performed on an
Icelandic population, as described in detail in the Supplemental
Experimental Procedures, yielding two loci of interest in the
GWLS for male obesity. In brief, individuals who exceeded a
BMI of 27 were classified as ‘‘affecteds’’ in the linkage analysis
and clustered into families with a genealogical database cov-
ering the entire nation, with the criterion that each affected was
related to at least one other affected by six or fewer meiotic
events. We report the results of our nonparametric affected-
only linkage analysis, together with gender-specific analyses
for dichotomous BMI (i.e., inclusive phenotypic groups of
BMI R 27, BMI R 30, BMI R 31 . BMI R 40) presentingetabolism 14, 671–683, November 2, 2011 ª2011 Elsevier Inc. 671
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Figure 1. Positional Cloning Identifies a
Linkage between Obesity and ARRDC3 in
Males
(A) Linkage region on chromosome 5 showing
strength of association to severe obesity (BMI >
33) in males (blue line), females (red line), and all
subjects (black line). The male-specific locus on
5q13–q15 (LOD 4.6) was identified using 51
pedigrees containing 124 affected males and 257
relatives. The female-only scan included 97 fami-
lies with 245 affected females and 612 relatives,
and the unrestricted analysis (all subjects) was
based on 168 families including 520 affecteds and
883 relatives.
(B) Strength of association after additional marker
genotyping in the 2-LOD drop for extremely obese
males compared to population controls. Results
are shown for single-marker association (black
dots) and two-, three- and four-marker haplotypes
(blue, green, and red dots, respectively).
(C) The genomic region of the peak haplotype
association contains a single RefSeq gene,
ARRDC3, in a discrete block of linkage disequi-
librium. See also Figure S1.
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ARRDC3 Regulates Obesitya propensity for overweight, mild obesity, severe obesity, and
morbid obesity, in a Caucasian population of 3893 males and
4445 females. Top linkage scores were observed for BMI > 33,
in male affecteds only, at 5q13–15 with distinct doublet peaks
at 89 cM and 107 cM, and a second locus was identified on
12q24 at 134 cM (Figure S1A).
Multiple investigators have previously reported linkages to
obesity and/or type II diabetes overlapping 5q12–15 (Hager
et al., 1998; Bell et al., 2004; Cheng et al., 2009). A noteworthy
candidate gene, PCSK1, is present at 5q14 (Kilpela¨inen et al.,
2009), but the sequence variation responsible for the linkage at
this locus has not been definitively identified. Further support
for the linkage of the doublet peaks at 5q13–q15 in humans
came from comparative mapping of major mouse quantitative
trait loci (QTL), which revealed a close synteny between the
human linkage peak and a mouse doublet QTL in chromosome
13 (Figures S1B–S1D). This mouse QTL was observed for mul-
tiple traits including fat mass and plasma levels of leptin and
insulin. We therefore genotyped an additional 27 markers in
the interval between 79 and 122 cM at 5q, bringing the informa-
tion content in the peak region up to 95%. This increased the
peak LOD score at marker D5S618 in the male-only analysis to
4.44 (Figure 1A).672 Cell Metabolism 14, 671–683, November 2, 2011 ª2011 Elsevier Inc.Given the strength of the LOD score
at 5q14–q15 and the syntenic match of
the doublet peaks in mice and man,
we carried out a locus-wide association
study across a 13 Mb region (83–96 Mb
in NCBI Build 34) that corresponds
roughly to a drop of 2 in LOD score under
the larger peak at 5q14–15. In addition to
the seven markers in this region used
for the linkage analysis, 171microsatellite
markers were genotyped, reaching an
average intermarker density of 78 kb.This set of markers was genotyped in an independent group of
435 severely obese males (BMIR 35) and 586 control subjects,
all from the same population that was used for the GWLS. In
addition to testing the alleles of each marker individually, we
also tested haplotypes based on these markers for association
to male obesity. The distribution of the markers across the locus
and the result of the association analysis are shown in Figure 1B.
The resulting at-risk haplotype (0 DG5S1387; 2 DG5S740;
0 DG5S1851; 4 DG5S744) was found at a frequency of 5.6% in
affected subjects and 1.5% in controls (p = 0.0000056; adjusted
p = 0.042; odds ratio = 3.8), and spanned the region 90.7 to 90.92
Mb. This region coincides with a single RefSeq gene in a dis-
crete linkage disequilibrium block, arrestin domain-containing
3 (ARRDC3), located at 90.76 Mb (Figure 1C).
Further analysis of the linkage conditional on the identified at-
risk haplotype revealed that noncarriers of the rare at-risk haplo-
type contribute the majority of the linkage signal at 5q13–15. The
inability to reveal a strong contribution of the mapped risk locus
to the linkage for obesity is nevertheless consistent with the
results for other gene linkages to common diseases identified
by positional cloning. For example, the well-confirmed associa-
tion of TCF7L2 alleles to type 2 diabetes showed no contribution
of the discovered at-risk alleles to the corresponding LOD score
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B Figure 2. Analysis ofARRDC3Gene Expres-
sion
(A) Northern analysis of ARRDC3 expression in
multiple human tissues.
(B) Northern analysis of human omental fat and
subcutaneous fat from two donors.
(C) Correlation of body mass index with ARRDC3
expression levels in omental and subcutaneous
adipose tissue measured by microarray analysis
(for omental adipose, n = 16males and 34 females;
for subcutaneous adipose, n = 325 males and 417
females). See also Figure S2.
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ARRDC3 Regulates Obesity(Grant et al., 2006). In light of these results, three possibilities
remain to explain the linkage signal to male obesity at 5q13–
15: the at-risk haplotype is correlated with an unidentified causal
variant with substantially higher risk, other at-risk haplotypes
across ARRDC3 exist, or there are other genes in the region
harboring risk of obesity in males.
In summary, we describe the clean identification of a single
gene in the linkage disequilibrium region; however, given a lack
of common SNPs that correlated with the relatively rare at-risk
microsatellite haplotype, including expression (e) SNPs, and
the inability to detect a strong contribution of the at-risk haplo-
type to the linkage signal, the human linkage analysis suggested
an association between ARRDC3 and male obesity but did not
fully prove a causal association. We therefore proceeded to
test for a causal connection of ARRDC3 to obesity with gene
expression studies in humans and knockout studies in mice.Cell Metabolism 14, 671–683, NARRDC3 Expression in Human
Omental Adipose Tissue Correlates
with BMI in Males
To define the distribution of ARRDC3 in
human tissues, we performed northern
analysis. A single transcript of 4.4 kb
was detected in placenta, skeletal mus-
cle, spleen, lungs, and liver; ARRDC3
transcripts were not detected in human
brain (Figure 2A). These results are con-
sistent with a previous report describing
Arrdc3 expression in mice, which also
identified prominent expression in skel-
etal muscle, placenta, and kidney but
relatively low expression in brain and
spinal cord (Oka et al., 2006). The low
neural expression of ARRDC3 was no-
table since few validated genes linked to
obesity have been identified with promi-
nent roles in peripheral tissues, especially
adipose tissue (O’Rahilly, 2009; Thorleifs-
son et al., 2009). We therefore performed
additional northern analysis in human adi-
pose samples and detected expression
of ARRDC3 in both omental and subcuta-
neous adipose (Figure 2B).
Given the robust expression of
ARRDC3 in adipose tissues, we next
tested whether ARRDC3 expression in
adipose tissue samples was associatedwith BMI. Omental fat tissue biopsies were collected from 50
volunteers who were either obese individuals undergoing gastric
bypass surgery or normal weight individuals undergoing elective
abdominal surgery. RNA was isolated from the tissues, and
microarray analyses were performed. Interestingly, ARRDC3
expression in omental adipose was significantly correlated with
BMI in males, whereas there was no significant correlation in
females (Figure 2C). The correlation of BMI with ARRDC3 ex-
pression inmales remained statistically significant (p < 0.05) after
removing the individual contributing most to the correlation. In
the less metabolically active subcutaneous adipose tissue,
ARRDC3 expression was not correlated with BMI (Figure 2C).
The association of ARRDC3 expression and BMI in males,
together with the male-specific linkage data, further suggest
but do not establish ARRDC3 as the gene underlying obesity
at this locus.ovember 2, 2011 ª2011 Elsevier Inc. 673
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Figure 3. ARRDC3 Is Upregulated by Fast-
ing in Humans and Mice
(A) ARRDC3 expression in human subcutaneous
adipose tissue biopsies from a microarray anal-
ysis. A randomized crossover design was used to
obtain paired fed and fasted data for each donor
(p < 0.001; n = 10).
(B) The data in (A) were combined with results of
microarray analysis from a second group of 10
donors who underwent fasting on both occasions
(combined p < 0.001; n = 20 fasted and 10 fed).
(C) Confirmation of the effect of feeding on Arrdc3
expression by real-time PCR (***p < 0.001; n = 10/
group).
(D) Arrdc3 expression in multiple mouse tissues in
response to a 14 hr fast (relative to mice fed ad
libitum) (*p < 0.05; n = 3–4/group).
(E) Northern analysis of tissues from fed and 14 hr
fasting mice. Muscle, heart, kidney, brain, and
spleen represent discontiguous lanes from a
single blot. Error bars represent mean ± SEM. See
also Figure S3.
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ARRDC3 Regulates ObesityTo define potential roles for ARRDC3 that might promote
obesity, we explored the expression of Arrdc3 in adipose tissue
in mice. We found no differences inArrdc3 expression in isolated
adipocytes compared to the stromal-vascular compartments in
either subcutaneous or visceral fat depots (Figure S2A). It has
been reported thatArrdc3 expression increased in human adipo-
cytes relative topreadipocytes (Okaet al., 2006), soweexamined
ARRDC3 protein levels during differentiation of 3T3-L1 preadipo-
cytes. On stimulation with differentiation medium, we observed
a rapid but transient increase in Arrdc3mRNA (data not shown).
We then analyzed cell lysates by western blotting with a new
monoclonal antibody to ARRDC3 that does not crossreact with
TXNIP or ARRDC4, detects an epitope in the C-terminal tail of
ARRDC3, and detects endogenous ARRDC3 in 3T3-L1 cell
lysates as a doublet band (Figures S2B–S2D). Western analysis
confirmed the transient increase and demonstrated correspon-
dence ofArrdc3mRNA toARRDC3protein levels during differen-
tiation (Figure S2E). However, ARRDC3 does not appear to
directly promote adipogenesis, as overexpression of ARRDC3
inhibited differentiation of 3T3-L1s (Figure S2F).674 Cell Metabolism 14, 671–683, November 2, 2011 ª2011 Elsevier Inc.ARRDC3 Is Induced by Fasting
in Humans and Mice
The fed-fasting transition plays an impor-
tant role in regulating metabolic activity
(Muoio and Newgard, 2006). We there-
fore examined whether ARRDC3 is impli-
cated in the fed or fasting gene-expres-
sion signature in human adipose tissue.
Microarray analysis of subcutaneous fat
biopsy tissues from fasted and fed volun-
teers identified 402 genes differentially
regulated between the fasted and fed
state (p < 0.01 as the threshold for sig-
nificance) (Figure S3A). ARRDC3 was
among the ten most responsive genes
to food intake, with ARRDC3 transcriptlevels higher during fasting (Figures 3A and 3B). This finding
was technically confirmed by real-time PCR analysis for
ARRDC3 (2.3-fold lower with feeding, p < 0.001) (Figure 3C).
Of note, TXNIP was another responder gene (p = 0.0007)
with higher expression during fasting (Figure S3B). Given the
similar responses to feeding, we tested whether expressions
of ARRDC3 and TXNIP were correlated in the larger sample of
subcutaneous adipose tissues described previously (Emilsson
et al., 2008) and found a significant positive correlation (r =
0.44, p < 0.001) (Figure S3C). These data support the notion
that ARRDC3 is a fasting-induced gene involved in regulating
metabolism and that these functions may be shared with other
human a-arrestins such as TXNIP.
To determine whether the response to fasting is conserved
across mammals, we measured Arrdc3 expression levels in
multiple tissues of mice fed ad libitum or fasted 14 hr. Real-
time PCR analysis showed that fasting induced Arrdc3 expres-
sion most prominently in visceral (epididymal) fat (5.6-fold),
with significant induction in brown fat (2.3-fold) and skeletal
muscle (3.9-fold) as well (Figure 3D). We then performed
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Figure 4. Arrdc3-Deficient Mice Are Resis-
tant to Age-Induced Obesity
(A) Total body mass of littermate wild-type (+/+),
heterozygous (+/), and homozygous (/)
Arrdc3 knockout mice from 5 to 20 weeks of age.
Male n = 10–18, 15–33, 6–11; female n = 9–10,
11–30, 7–14 for +/+, +/, and / genotypes,
respectively.
(B) Perigonadal fat mass expressed as a per-
centage of total body mass at 5–7 months of age.
Male n = 7, 6, 3; female n = 6, 9, 5.
(C) Adiposity of male and female littermates
measured by DEXA scanning at 8–12 weeks of
age. Male n = 7, 6, 4; female n = 6, 7, 5. Error bars
represent mean ± SEM; *p < 0.05; **p < 0.01; ***p <
0.001 versus wild-type. See also Figure S4.
Cell Metabolism
ARRDC3 Regulates Obesitynorthern analysis and confirmed a striking induction of Arrdc3 by
fasting in visceral fat and skeletal muscle (Figure 3E).
Generation of Arrdc3-Deficient Mice
Arrdc3-deficient mice were generated from a BayGenomics
gene-trap clone containing an insertional mutation between
exons 1 and 2 of Arrdc3 (Figure S4A). Intercrossing heterozy-
gous mice yielded homozygous offspring at the expected
Mendelian ratio; however, there was significant perinatal mor-
tality in homozygous pups. Of 631 mice surviving to weaning,
187 were wild-type (30%), 399 (63%) were heterozygotes, and
45 (7.1%) were homozygotes. Of the 45 homozygotes, 19
(42%) were male and 26 (58%) were female (p = 0.29 for differ-
ence from 50%). Transmission of the insertional mutation in
Arrdc3 was confirmed by Southern analysis of genomic DNA
digested with two different restriction enzymes (Figure S4B);
the loss ofArrdc3 expression was documented by northern anal-
ysis (Figure S4C).
Arrdc3-Deficient Mice Are Resistant to Age-Induced
Obesity
We tested whether Arrdc3-deficient male and female mice are
resistant to obesity with age compared to wild-type littermate
controls. C57BL/6 mice are prone to increased adiposity and
insulin resistance on a chow diet by 18 weeks of age (Biddinger
et al., 2005). We therefore weighed wild-type (+/+) mice as well
as heterozygous (+/) and homozygous (/) Arrdc3 knockout
mice from weaning through 20 weeks of age (Figure 4A). TotalCell Metabolism 14, 671–683, Nbody mass of male Arrdc3 null mice
was lower than wild-type littermates at
5 weeks of age (15% lower, p < 0.001)
and at 20 weeks of age (29% lower, p <
0.001). The effect of Arrdc3 deficiency
on body weight was dependent on gene
dosage; the weights of heterozygotes
were lower than wild-type mice at
12 weeks of age (7.3% less, p < 0.05).
The effect of Arrdc3 deficiency in
female mice was not as strong as in
male mice, with little effect in young
female mice. Total body mass of Arrdc3
null females was not different from wild-type littermates at 5 weeks of age (/, 19.3 ± 0.5 g; +/+,
19.3 ± 0.8 g). However, Arrdc3 null females were resistant to
weight gain with age: at 20 weeks, body weight in Arrdc3 null
mice was 29% lower than in wild-type mice (33.9 ± 3.0 g versus
47.4 ± 1.9 g; p < 0.01). Heterozygous female mice also trended
toward lower body mass than wild-type mice at 20 weeks of
age (41.3 ± 2.6 g versus 47.4 ± 1.9 g; p = 0.08).
Since Arrdc3 null mice were shorter than wild-type mice, we
directly tested whether adiposity as a percentage of total body
mass was different in Arrdc3 null mice. First, we dissected out
and weighed fat pads of the older mice (5–7 months old) and
calculated fat mass as a percentage of total body mass. Perigo-
nadal fat pads were smaller in Arrdc3 null mice compared to
wild-type mice in both males (1.9 ± 0.4% versus 3.6 ± 0.3% of
total body mass, p < 0.05) and females (4.4 ± 0.9% versus
11.2 ± 0.9% of total body mass, p < 0.001) (Figure 4B). We
then confirmed by DEXA scanning that differences in whole
body adiposity are present just as differences in body mass
are emerging, at 2–3 months of age (Figure 4C). Percentage
body fat was lower in Arrdc3 null mice compared to wild-type
mice in males (22.1 ± 1.3% versus 34.1 ± 0.8%, p < 0.001) and
females (27.6 ± 2.6% versus 44.9 ± 4.0%, p < 0.01).
Arrdc3-Deficient Mice Retain Normal Glucose
Homeostasis
In general, mouse models and human disease states with low
adiposity can be accompanied either by normal glucose homeo-
stasis or by a lipodystrophy-like insulin resistance syndromeovember 2, 2011 ª2011 Elsevier Inc. 675
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ARRDC3 Regulates Obesity(Huang-Doran et al., 2010). We therefore tested the glucose
tolerance and insulin response of male and female Arrdc3-
deficient mice compared to wild-type littermates at 5–6 months
of age.
Prior to injection of insulin, mice were fasted for 4 hr and base-
line blood glucose levels were measured (Figure 5A). Fasting
glucose levels were elevated in wild-type mice and reduced in
a gene dosage-dependent fashion in both male and female
Arrdc3-deficient mice, consistent with protection from the
hyperglycemia and insulin resistance that develops in the wild-
type C57BL/6 mice with age (Biddinger et al., 2005). Intraperito-
neal injection of a low dose (0.25 mU/g) of insulin had little effect
on glucose levels inwild-type andheterozygousmice (Figure 5B).
In contrast, Arrdc3 null mice retained a strong and sustained
response to a low dose of insulin, with significantly lower glucose
levels at 30, 60, and 90 min after injection compared to wild-type
littermates. Male and female Arrdc3 null mice also cleared an
intraperitoneal glucose load more quickly, with significantly
lower glucose levels 30 min after injection (Figure 5C). Further-
more, we measured insulin levels in 3-month-old mice fed ad
libitum (Figure 5D).Wild-typemice hadmuch higher insulin levels
than the Arrdc3 null mice, which retained insulin levels in the
normal range (Andrikopoulos et al., 2008). These data demon-
strate that Arrdc3 deficiency protects against obesity while
maintaining normal insulin response and glucose homeostasis.
Obesity with insulin resistance is often accompanied by
increased lipid stores in the liver (Unger et al., 2010). Histological
analysis of a 9-month-old wild-type mouse showed evidence of
hepatic steatosis (Figure 5E), whereas the liver of an Arrdc3 null
littermate lacked overt lipid accumulation. Similarly, wild-type
interscapular brown fat showed lipid-laden cells, whereas
Arrdc3 null brown fat showed minimal lipid deposition. Finally,
histology of adjacent subcutaneous white fat was consistent
with smaller adipocyte size in the Arrdc3 null mice.
Arrdc3-Deficient Mice Have Increased Energy
Expenditure with Thermogenic Activation of Brown
and White Adipose Tissue
We next sought to identify potential mechanisms for resistance
to obesity in Arrdc3 null mice. However, male Arrdc3 null mice
weighed less than wild-type mice even at the time of weaning,
raising the possibility that observed differences in outcomes
could be confounded by differences in growth and develop-
ment. Therefore, we focused on analyzing Arrdc3 deficiency in
female mice.
Serum chemistry and hormone levels of 12- to 15-week-old
female mice (Table S1) showed that Arrdc3 null mice had lower
leptin levels, consistent with the lower adiposity, as well as lower
triglyceride levels and higher beta-hydroxybutyrate levels. The
markedly lower leptin and insulin levels provide additional
support for Arrdc3 as the gene underlying the mouse QTLs for
insulin and leptin levels on chromosome 13 (Figure S1B).
However, there was no evidence for altered hormone levels as
a primary cause for resistance to obesity.
To investigate energy balance, we measured food intake in
female mice just as differences in body mass were appearing
among genotypes (at 8–10 weeks of age). Food intake was not
significantly different among genotypes (Figures S5A–S5C). In
contrast, feed efficiency (change in body weight per calorie676 Cell Metabolism 14, 671–683, November 2, 2011 ª2011 Elsevierconsumed) was lower in the Arrdc3 null mice compared to
wild-type littermates (/, 0.7 ± 4.5 mg/kcal; +/, 5.7 ±
3.1mg/kcal; +/+: 14.9 ± 4.1mg/kcal; p < 0.05 for/ versus +/+;
p = 0.09 for +/ versus +/+) (Figure 6A). While not excluding
a contribution from reduced appetite, the markedly low
feed efficiency suggested that Arrdc3 null mice resist obesity
through either decreased nutrient absorption or increased
energy expenditure.
To test directly whether decreased Arrdc3 levels cause
increased energy expenditure, gas exchange and activity levels
were monitored by housing mice in metabolic cages. Interpreta-
tion of causality in metabolic cage analysis is most clear in
groups of mice with the same body mass and composition
(Butler and Kozak, 2010), yet even female Arrdc3 null mice trend
toward lower body mass by 8–12 weeks of age. We therefore
tested whether we could detect a difference between Arrdc3
wild-type and Arrdc3 heterozygous female mice in the metabolic
cage analysis, since these mice have similar body mass and
composition at 8–12 weeks of age. The analysis showed that
Arrdc3 +/ mice had significantly higher oxygen uptake (Fig-
ure S5D) and higher calculated heat production than wild-type
littermates, particularly during the dark (active) cycle (Figure 6B),
demonstrating that decreased levels of ARRDC3 lead to an
increase in energy expenditure. The respiratory exchange ratio
(Figure S5E) did not show significant differences in fuel source
usage. Activity levels were also significantly increased in
Arrdc3 +/ mice, primarily at the light-to-dark feeding transition
(Figure 6B), suggesting that increased energy expenditure in the
mice is attributable to both increased basal metabolic rate and
increased activity.
Given that Arrdc3 is regulated by feeding status in visceral
white adipose and brown adipose tissues, we hypothesized
that adipose tissue might be a source for the increased energy
expenditure. Since brown fat is a major site of energy expendi-
ture in mice (Foster and Frydman, 1979), we first examined
whether Arrdc3 null female mice have increased brown fat ther-
mogenic function. At room temperature, we observed a trend
toward lower body temperature in the Arrdc3-deficient mice
(/, 37.3 ± 0.4C; +/, 37.6 ± 0.2C; +/+, 37.7 ± 0.2C; p =
0.40 for / versus +/+; p = 0.92 for +/ versus +/+), which
could reflect increased heat loss from either lower subcutaneous
adiposity or decreased sympathetic activation (Thomas and
Palmiter, 1997). However, when housed at 4C, Arrdc3 null
mice recovered their baseline body temperature more rapidly.
Compared to wild-type littermates, Arrdc3 null mice were signif-
icantly warmer 4, 6, and 8 hr after being housed at 4C (Fig-
ure 6C). After 12 hr at 4C, all mice had returned to similar
body temperatures relative to baseline. This indicates that
Arrdc3 does not affectmaximal levels of thermogenesis. Instead,
the time course of early recovery suggests that Arrdc3 null mice
have baseline differences that prime them to respond more
rapidly to the cold.
The initial nonshivering thermogenic response to cold is
largely due to a hypothalamus-driven increase in sympathetic
tone (Thomas and Palmiter, 1997) that stimulates b-adrenergic
receptors in the brown fat, inducing cAMP, lipolysis, local thyroid
hormone signaling, and UCP1 levels (Jimenez et al., 2002; de
Jesus et al., 2001). However, at baseline, serum concentrations
of 3,5,30-triiodothyronine (T3), thyroxine (T4), epinephrine, andInc.
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Figure 5. Arrdc3-Deficient Mice Are Resistant to the Metabolic Complications of Obesity
(A) Fasting blood glucose levels of littermate wild-type (+/+), heterozygous (+/) and homozygous (/) Arrdc3 knockout mice at 5–7 months of age. Male n = 6,
11, 3; female n = 7, 9, 6 for +/+, +/, and / genotypes, respectively.
(B) The samemice were then injected with low-dose (0.25 mU/g body mass) insulin into the peritoneum. Response of blood glucose levels to insulin is expressed
relative to the baseline levels shown in (A).
(C) Glucose tolerance testing of male and female littermatemice at 5–6months of age. Blood glucose levels weremeasured after an intraperitoneal injection of 2 g
glucose/kg body mass. Male n = 6, 10, 3; female n = 5, 11, 7.
(D) Insulin levels in fed mice at 3 months of age. Male n = 8, 10, 3; female n = 5, 13, 7.
(E) Histological analysis of a 9-month-old male wild-type mouse and an Arrdc3 / littermate. Images are representative of those observed in 3 mice of each
genotype. Scale bars, 10 mm. Error bars represent mean ± SEM; *p < 0.05; **p < 0.01 versus wild-type.
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Figure 6. Arrdc3-Deficient Mice Have Increased Energy Expenditure and Adipose Tissue Activation
(A) Food intake of 8- to 10-week-old female mice wasmeasured over 1 week and feed efficiency calculated as the ratio of weight gain to energy intake. n = 11, 17,
6 for +/+, +/, and / genotypes, respectively.
(B) Metabolic cage analysis of Arrdc3 haploinsufficient and wild-type mice (n = 8 and 9 for +/+ and +/ genotypes, respectively).
(C) Brown fat thermogenic function was assessed by housing mice at 4C. Rectal temperature was measured and expressed relative to baseline temperature
(n = 6, 9, and 5).
(D) Serum T3 levels in 3-month-old female mice (n = 5, 13, 6).
(E–F) Serum catecholamine levels in 3-month-old female mice (n = 5, 14, 7).
(G) Real-time PCR analysis of catecholamine-stimulated genes in brown adipose tissue of 3-month-old mice (n = 4, 5, 3).
(H) Type 2 deiodinase activity in brown adipose tissue lysates (n = 5, 9, 5).
(I) Real-time PCR analysis of thermogenic genes in visceral white adipose tissue (n = 4, 5, 3). Error bars represent mean ± SEM; *p < 0.05; **p < 0.01 versus
wild-type. See also Figure S5 and Table S1.
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Figure 7. ARRDC3 Interacts with b-Adren-
ergic Receptors to Regulate Signaling in
Adipose Tissue
(A) Coimmunoprecipitation of HA-tagged b2-
adrenergic receptorwith FLAG-taggeda-arrestins.
(B) Coimmunoprecipitation of b3-adrenergic re-
ceptor with ARRDC3.
(C) Glycerol release from cultured white adipose
tissue in response to norepinephrine (n = 3 mice/
genotype).
(D) Time course of cyclic AMP levels in white
adipose tissue in response to norepinephrine
(n = 3 mice/genotype). Error bars represent
mean ± SEM; *p < 0.05 versus wild-type.
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were either not significantly different, or were lower, than those
of wild-type littermates (Figures 6D–6F and Table S1). The
normal-to-low systemic thyroid and catecholamine levels,
together with the expression pattern of Arrdc3, suggested that
a primary effect of Arrdc3 is downstream of systemic hormones
and at the level of the effector tissues such as brown fat.
We therefore harvested brown adipose tissue of the female
mice (3 months old) and performed real-time PCR analysis of
the catecholamine-induced genes Dio2 (Silva and Larsen,
1983), Gmpr (Salvatore et al., 1998), Ucp1 (Mory et al., 1984),
and Pgc1a (Puigserver et al., 1998) (Figure 6G). Arrdc3 defi-
ciency increased baseline levels of Dio2 transcripts in a gene
dosage-dependent manner relative to wild-type (+/, 1.8-fold
increase; /, 3.1-fold increase; p = 0.14 for +/ versus +/+,
p < 0.01 for/ versus +/+), whereasUcp1 andPgc1a transcript
levels were unchanged. Dio2 encodes the type 2 iodothyronine
deiodinase (D2), which converts thyroxine to active T3 within
tissues and is required for cold-induced nonshivering thermo-
genesis (de Jesus et al., 2001). We measured D2 activity in the
brown fat and confirmed a 10-fold increase in Arrdc3 null
brown fat compared with wild-type brown fat (+/+, 0.34 ±
0.05; +/, 1.3 ± 0.5; /, 4.5 ± 1.4 fmol/min/mg total protein;
p = 0.07 for +/ versus +/+, p < 0.05 for / versus +/+)
(Figure 6H).
Although we observed differences in brown fat activation,
Arrdc3 is most strongly regulated in the visceral adipose tissue
depot. While the interscapular brown fat depot is a major site
of thermogenesis in rodents, it has recently been demonstrated
that the distinction between white and brown fat is not absolute:
white adipose tissue is interspersed with varying proportions of
Ucp1-expressing cells resembling brown adipocytes (Ishibashi
and Seale, 2010), and the relative numbers of these cells areCell Metabolism 14, 671–683, Nincreased by b-adrenergic signaling
(Cousin et al., 1992). Therefore, we tested
whether visceral white fat could also
contribute to increased baseline thermo-
genesis through ‘‘browning’’ of the white
fat. Analysis of mRNA extracted from
visceral fat revealed a striking 30-fold up-
regulation in Ucp1 levels in Arrdc3 null
mice relative to wild-type mice (Figure 6I).
Expression of Pgc1a, a master transcrip-tional regulator of thermogenesis (Puigserver et al., 1998), was
also significantly increased in Arrdc3 null and Arrdc3 heterozy-
gous mice relative to wild-type mice (7.7-fold and 2.6-fold in-
creases, respectively).
Taken together, these data show that Arrdc3 null mice have
increased thermogenic capacity due in part to upregulation of
the thermogenic program in both brown and white fat depots.
This occurs in the absence of increased stimulation by systemic
catecholamines and thyroid hormone, consistent with regulation
of local intracellular signaling by Arrdc3.
ARRDC3 Regulates Adipose Tissue Response to
Catecholamines through Interaction with b-Adrenergic
Receptors
Although the molecular functions of the a-arrestins are currently
unclear inmice and humans, several studies in yeast have shown
that regulation of receptor turnover and endocytosis is an
ancient function of the arrestin-fold proteins (Lin et al., 2008; Her-
rador et al., 2010). Recently, Nabhan and colleagues have
reported that ARRDC3 interacts with the b2-adrenoceptor re-
sulting in receptor ubiquitination in vitro (Nabhan et al., 2010),
suggesting the hypothesis that loss of ARRDC3 leads to en-
hanced energy expenditure through increased intracellular
b-adrenergic signaling.
We first tested whether interaction with the b-adrenoceptor,
a defining characteristic of the b-arrestins, is also a property of
the a-arrestins. Four human a-arrestins and the b2-adrenergic
receptor were overexpressed in 293 cells, and the interaction
tested by coimmunoprecipitation (Figure 7A). No interaction
between the b2-adrenoceptor and TXNIP was detected, and
a weak interaction was observed with ARRDC1. In contrast,
a robust interaction was detected with both ARRDC3 and
ARRDC4, suggesting that interaction with the b2-adrenoceptorovember 2, 2011 ª2011 Elsevier Inc. 679
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amine stimulation induces the brown adipocyte thermogenic
program largely through the b3-adrenoceptor, we next tested
whether ARRDC3 also interacts with this receptor (Figure 7B).
Immunoprecipitation of ARRDC3 revealed a strong interaction
with the b3-adrenoceptor, supporting the hypothesis that
ARRDC3 generally regulates b-adrenergic signaling.
Finally, we tested whether the in vitro interaction of ARRDC3
and the b-adrenoceptors is accompanied by a significant effect
on adipose tissue function. We used a well-established func-
tional assay, adrenergic stimulation of lipolysis in cultured
adipose tissue (Bjo¨rntorp, 1966), to assess the response to cate-
cholamines in the absence of ARRDC3. Stimulation of excised
visceral white adipose tissue with norepinephrine produced
significantly higher glycerol release from Arrdc3 null animals
compared to wild-type animals (Figure 7C). Since b-adrenergic
signaling is largely mediated by cAMP, we also examined
cAMP levels after stimulation by norepinephrine and found
significantly higher cAMP levels in adipose tissue from Arrdc3
null mice compared to tissue from wild-type mice (Figure 7D).
DISCUSSION
In the current study, we describe an association of high BMI in
males to a rare haplotype across a single gene,ARRDC3, encod-
ing a member of the arrestin superfamily of proteins. In addition,
higher expression of ARRDC3 in visceral adipose tissue was
associated with obesity in males. Motivated by the suggestion
of a role for ARRDC3 in human obesity, we generated Arrdc3-
deficient mice and demonstrated that Arrdc3 regulates obesity
in mice. Arrdc3-deficient mice were resistant to obesity in a
gene dosage-dependent manner in both genders, but with
greater effect in males than in females. Arrdc3 deficiency pro-
tects from obesity through increased energy expenditure, in
part through enhanced thermogenesis in brown and white
adipose tissue. Finally, we show that ARRDC3 interacts directly
with b2- and b3-adrenoceptors, resulting in increased intrinsic
adipose tissue b-adrenergic signaling.
Our work identifies ARRDC3 as the second a-arrestin
that regulates metabolic processes in vivo. Despite the shared
ability to regulate metabolism, ARRDC3 and its homologous
a-arrestins appear to operate by distinct molecular mechanisms.
In vitro, TXNIP and ARRDC4 strongly inhibit glucose uptake into
cells but ARRDC3 does not (Patwari et al., 2009). This is mirrored
by differences in the phenotype of the Txnip null and Arrdc3
null mice. Txnip null mice have a profound fasting hypoglycemia
with downregulated insulin levels due to increased peripheral
tissue glucose uptake (Hui et al., 2008; Chutkow et al., 2010),
whereas Arrdc3-deficient mice maintain glucose and insulin
levels within the normal range. Most strikingly, Txnip null mice
are one of the few animal models that decouple the development
of obesity from the development of insulin resistance: they are
strongly protected against the development of diabetes despite
increased adiposity (Chen et al., 2008; Chutkow et al., 2010),
reminiscent of PPAR-gamma agonist therapy and adiponectin-
overexpressing mice (Kim et al., 2007). In contrast, Arrdc3 null
mice show no decoupling of adiposity and insulin resistance:
they are protected against both obesity and dysregulated
glucose homeostasis.680 Cell Metabolism 14, 671–683, November 2, 2011 ª2011 ElsevierArrdc3 is expressed in multiple nonneural tissues and may
have more than one site of action. Furthermore, both increased
metabolic rate and increased activity levels contributed to
increased energy expenditure in the Arrdc3-deficient mice, and
either one alone may be causal due to the interwoven control
of these processes (Xu et al., 2011). However, we identify here
that increased energy expenditure in Arrdc3-deficient mice is
accompanied by more rapid cold-induced thermogenesis and
activation of the thermogenic program in brown and white
adipose tissue. In brown fat, we found upregulated tissue iodo-
thyronine D2 activity. Increased conversion of T4 to active T3
locally via D2 has been shown to confer resistance to diet-
induced obesity (Watanabe et al., 2006). Surprisingly, we saw
no increase in Ucp1 expression in brown adipose tissue of
Arrdc3-deficient mice. Consistent with these results, UCP1 is
not required for increased oxygen consumption when mice are
placed on a high-fat diet (Anunciado-Koza et al., 2008). On the
other hand, Ucp1 and Pgc1a were strongly induced in white
fat, and this ‘‘browning’’ of the white fat is now known to be
a mechanism for upregulating thermogenesis and resisting
obesity (Ishibashi and Seale, 2010).
Whereas multiple human studies consistently found that
ARRDC3 is associated with obesity only in males, and Arrdc3
null male mice were more strongly affected, Arrdc3 null mice of
both genders were resistant to obesity. This may be attributable
to species differences, such as the well known divergences
in regulation of energy expenditure, hormone response, and
steroid hormone levels betweenmice and humans (vanWeerden
et al., 1992; Farooqi et al., 1999). On the other hand, complete
loss of Arrdc3 in mice is likely not directly comparable to the
naturally occurring variation in ARRDC3 that was studied in
humans.
It is possible that the observed results for the Arrdc3 null mice
are biased by perinatal mortality. However, this is unlikely to
affect the ultimate conclusion that ARRDC3 regulates obesity,
for several reasons. First, newborn Arrdc3 null pups are born
at the expected Mendelian ratios, are able to breathe and feed,
and have no detectable developmental defects. Second, in-
creased perinatal mortality would be expected to bias against
our hypothesis, since surviving pups are likely to have more
robust growth than a hypothetical average that would include
pups that did not survive. Finally, and most importantly, there
was no increase in perinatal mortality for Arrdc3 +/ mice, yet
most of the observed phenotypes show an Arrdc3 gene dose-
dependent relationship.
Our data, together with two recent reports (Nabhan et al.,
2010; Draheim et al., 2010), suggest the hypothesis that
ARRDC3 retains a role in downregulating receptor signaling,
a defining feature of the classical arrestins. However, a precise
delineation of ARRDC3 function in receptor endocytosis is still
needed. Although recruitment of ARRDC3 to the b2-adrenocep-
tor is increased on stimulation by ligand (Nabhan et al., 2010), it is
not clear whether binding of ARRDC3 is as specific for phos-
phorylated receptors as the arrestins. The residues in the arrestin
polar core which are critical for this binding specificity are not
conserved in the a-arrestins. In addition, the b3-adrenoceptor
lacks the phosphorylation sites that lead to rapid downregulation
in the b1 and b2 adrenoceptors (Nantel et al., 1993; Liggett
et al., 1993), so investigation of the interaction and effects onInc.
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will be required to define the significance of the interaction.
In summary, we demonstrate that Arrdc3-deficiency protects
against obesity through increased energy expenditure and sug-
gest that ARRDC3 acts by increasing b-adrenergic signaling to
activate thermogenesis in brown and white adipose tissues.
EXPERIMENTAL PROCEDURES
Subjects
Ethical approval for the study was granted by the National Bioethics
Committee (NBC 01-033) and the Icelandic Data Protection Authority. All
participants in the study signed informed consent. The study is based on
a subset of a large cohort of 8338 Icelandic individuals who have participated
in genetic studies of cardiovascular diseases and related comorbidities at
deCODE Genetics. Most of the cohort did not have a history of cardiovascular
disease but had been recruited as unaffected relatives of cardiovascular
probands or as controls.
Adipose Tissue Isolation and Gene Expression Analysis
Abdominal subcutaneous fat samples were obtained as described previously
(Emilsson et al., 2008) from a population-based cohort with a distribution of
BMI typical for a developed Western country. Visceral fat removal from 50
subjects was performed as follows: 10–20 g of adipose tissue samples from
the greater omentum of subjects who were either obese individuals under-
going gastric bypass surgery or normal weight individuals undergoing elective
abdominal surgery. Fat samples were removed with an ultrascissor (or by
diathermy) and then placed in a plastic bag and moved through a 12 mm
port. Before surgery, all subjects were fasted overnight, and only saline and
the necessary premedication and anesthetics were infused intravenously until
adipose tissue was removed. All samples were removed under general anes-
thesia. The samples were immediately frozen in liquid nitrogen and stored
at 70C.
For technical replication, ARRDC3 expression was quantified by real-time
PCR with TaqMan assays spanning exons 7–8 of ARRDC3 and normalized
to b-actin. Each sample was run in quadruplicate on an ABI Prism 7900HT
machine. For northern blot analysis of visceral and subcutaneous adipose
tissue, 5 mg of RNA was loaded per well where quantification of total RNA
was carried out using the comparative CT method according to the manufac-
turer’s recommendations (User Bulletin #2, ABI Prism 7700 Sequence Detec-
tion System). For analysis of other human tissues, multiple tissue northern
blots were obtained from Clontech (Human MTN Blot Cat. 7760-1). Mem-
branes were probed with 32P-labeled full-length human ARRDC3 cDNA and
a commercially available probe for the housekeeping gene b-actin.
Fed-Fasting Transcriptional Analysis in Subcutaneous Fat
Subcutaneous fat biopsies were obtained sequentially (one week apart) from
20 human donors (14 females, 6 males). One group of 10 subjects was as-
signed to fasting on both occasions while another group of 10 entered
a two-arm randomized crossover study, in which each subject participated
in both a fasting and a feeding arm of the study. All individuals fasted beginning
at 9 p.m. on the day before the biopsy. Individuals were randomly assigned to
one of two groups: the fasted group, in which the individual fasted throughout
the morning until noon, or the fed group, in which the individual consumed
a meal between 9 and 10 a.m. For each arm of the study, subcutaneous
adipose tissue was collected 2 hr after the meal or a matching time after over-
night fasting. RNA was isolated from each of the samples andmicroarray anal-
ysis performed for 23,720 genes, as detailed previously (Emilsson et al., 2008).
For mouse experiments, male C57BL/6Tac mice were either fasted over-
night for 14 hr or fed ad libitum before tissue harvest. Tissues were disrupted
and RNA extracted in TRI Reagent (Molecular Research Center, Inc., Cincin-
nati, OH). RNA was reverse transcribed and Arrdc3 mRNA quantified by
real-time PCR analysis with primers spanning exons 1–2.
Arrdc3-Deficient Mice
The BayGenomics mouse ES cell line CSE151 (129/OlaHsd strain) containing
the insertion of a promoterless gene-trap cassette (pGT0lxf) between exonsCell M1–2 of Arrdc3 was identified by 50-RACE and PCR analysis (Stryke et al.,
2003). Mouse chimeras generated from the targeted clone were bred with
C57BL/6 mice, and heterozygous offspring were bred to yield Arrdc3 null
and wild-type littermates that were used for all experiments in this study.
Mouse Studies
All experiments were approved by the Harvard Medical Area Standing
Committee on Animals. Mice were fed a breeding diet (PicoLab Mouse Diet
20) with an energy content of 23% protein, 21% fat, and 55% carbohydrates
and were housed in microisolator cages. Insulin tolerance tests in mice were
performed by injecting 0.25 mU/g regular insulin intraperitoneally (IP) after
4 hr of fasting. Glucose tolerance tests were performed by IP injection of
2 g/kg glucose after 6 hr of fasting. Blood was collected from the tail vein at
30 min intervals and measured by glucometer (Contour, Bayer). Food intake
was measured by weighing food remaining in cages of mice housed individu-
ally for 1 week. For cold tolerance testing, mice were housed at 4C in micro-
isolator cages with ad libitum access to food and water. For northern analysis,
10 mg of total RNA was loaded per lane and membranes probed with
32P-labeled full-length Arrdc3 DNA. Realtime PCR analysis was performed
with primers as described in the Supplemental Experimental Procedures
and quantified by the comparative CT method relative to expression of Tbp
(Lossos et al., 2003).
Statistical Analysis
All data is displayed as mean ± SEM. Inferences about differences between
means were tested by two-tailed Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information included five figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2011.08.011.
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